| Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 5997 | 2015 |
| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2358 | 2014 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2179 | 2017 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1734 | 2018 |
| Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma GV Long, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 377 (19), 1813-1823, 2017 | 1481 | 2017 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1086 | 2016 |
| Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study GV Long, V Atkinson, S Lo, S Sandhu, AD Guminski, MP Brown, ... The Lancet Oncology 19 (5), 672-681, 2018 | 875 | 2018 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 795 | 2017 |
| Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled … PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ... The Lancet Oncology 21 (11), 1465-1477, 2020 | 431 | 2020 |
| Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 342 | 2019 |
| Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial PA Ascierto, GV Long, C Robert, B Brady, C Dutriaux, AM Di Giacomo, ... JAMA oncology 5 (2), 187-194, 2019 | 342 | 2019 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 328 | 2020 |
| Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma R Dummer, A Hauschild, M Santinami, V Atkinson, M Mandalà, ... New England Journal of Medicine 383 (12), 1139-1148, 2020 | 319 | 2020 |
| Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma A Ribas, D Lawrence, V Atkinson, S Agarwal, WH Miller Jr, MS Carlino, ... Nature medicine 25 (6), 936-940, 2019 | 302 | 2019 |
| Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma PA Ascierto, PF Ferrucci, R Fisher, M Del Vecchio, V Atkinson, H Schmidt, ... Nature medicine 25 (6), 941-946, 2019 | 289 | 2019 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 287 | 2021 |
| Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma M Sznol, PF Ferrucci, D Hogg, MB Atkins, P Wolter, M Guidoboni, ... J Clin Oncol 35 (34), 3815-3822, 2017 | 283 | 2017 |
| Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ... The Lancet Oncology 18 (9), 1202-1210, 2017 | 276 | 2017 |
| Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ... The Lancet Oncology 18 (9), 1202-1210, 2017 | 276 | 2017 |
| Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600–mutant stage III melanoma A Hauschild, R Dummer, D Schadendorf, M Santinami, V Atkinson, ... Journal of Clinical Oncology 36 (35), 3441, 2018 | 267 | 2018 |
